Adaptimmune Income Tax Expense from 2010 to 2024

ADAP Stock  USD 1.13  0.12  11.88%   
Adaptimmune Therapeutics Income Tax Expense yearly trend continues to be relatively stable with very little volatility. Income Tax Expense is likely to grow to about -13.5 M this year. During the period from 2010 to 2024, Adaptimmune Therapeutics Income Tax Expense destribution of quarterly values had range of 16.8 M from its regression line and mean deviation of  3,174,368. View All Fundamentals
 
Income Tax Expense  
First Reported
2013-06-30
Previous Quarter
-4.4 M
Current Value
-526 K
Quarterly Volatility
761 K
 
Yuan Drop
 
Covid
Check Adaptimmune Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptimmune main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 M, Interest Expense of 1.6 M or Selling General Administrative of 37.2 M, as well as many exotic indicators such as Price To Sales Ratio of 2.5, Dividend Yield of 0.0 or PTB Ratio of 4.24. Adaptimmune financial statements analysis is a perfect complement when working with Adaptimmune Therapeutics Valuation or Volatility modules.
  
This module can also supplement Adaptimmune Therapeutics' financial leverage analysis and stock options assessment as well as various Adaptimmune Therapeutics Technical models . Check out the analysis of Adaptimmune Therapeutics Correlation against competitors.

Latest Adaptimmune Therapeutics' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Adaptimmune Therapeutics Plc over the last few years. It is Adaptimmune Therapeutics' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptimmune Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Slightly volatile
   Income Tax Expense   
       Timeline  

Adaptimmune Income Tax Expense Regression Statistics

Arithmetic Mean(2,053,117)
Geometric Mean1,198,109
Coefficient Of Variation(242.09)
Mean Deviation3,174,368
Median(878,673)
Standard Deviation4,970,406
Sample Variance24.7T
Range16.8M
R-Value(0.42)
Mean Square Error21.9T
R-Squared0.18
Significance0.12
Slope(468,373)
Total Sum of Squares345.9T

Adaptimmune Income Tax Expense History

2024-13.5 M
2023-14.3 M
20222.5 M
2021791 K
2020162 K
2019242 K
2018497 K

About Adaptimmune Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Adaptimmune Therapeutics income statement, its balance sheet, and the statement of cash flows. Adaptimmune Therapeutics investors use historical funamental indicators, such as Adaptimmune Therapeutics's Income Tax Expense, to determine how well the company is positioned to perform in the future. Although Adaptimmune Therapeutics investors may use each financial statement separately, they are all related. The changes in Adaptimmune Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adaptimmune Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Adaptimmune Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Adaptimmune Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense-14.3 M-13.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Adaptimmune Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptimmune Therapeutics Plc Stock. Highlighted below are key reports to facilitate an investment decision about Adaptimmune Therapeutics Plc Stock:
Check out the analysis of Adaptimmune Therapeutics Correlation against competitors.
Note that the Adaptimmune Therapeutics information on this page should be used as a complementary analysis to other Adaptimmune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Adaptimmune Stock analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Is Adaptimmune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.72)
Revenue Per Share
0.3
Quarterly Revenue Growth
(0.98)
Return On Assets
(0.28)
Return On Equity
(1.88)
The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.